Сосудистые когнитивные нарушения у пациентов с сердечной недостаточностью: распространенность, факторы риска, последствия и стратегии лечения

1. Клинические рекомендации. Когнитивные расстройства у лиц пожилого и старческого возраста. Всероссийское общество неврологов, Общественная организация «Российское общество психиатров», Общероссийская общественная организация «Российская ассоциация геронтологов и гериатров» Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 617_5. Доступ: https://cr.minzdrav.gov.ru/view-cr/617_5 (дата обращения – 11.09.2025). (Clinical guidelines. Cognitive impairment in the elderly and senile. All-Russian Society of Neurologists, Russian Society of Psychiatrists, Russian Association of Gerontologists and Geriatricians. Rubricator of the clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 617_5.

URL: https://cr.minzdrav.gov.ru/view-cr/617_5 (date of access – 11.09.2025) (In Russ.)).

2. Танашян М.М., Антонова К.В. Цереброметаболическое здоровье. Анналы клинической и экспериментальной неврологии. 2025;19(2):62–73. (Tanashyan MM, Antonova KV. Cerebrometabolic health. Annaly klinicheskoy i eksperimental’noy nevrologii = Annals of Clinical and Experimental Neurology. 2025;19(2):62–73 (In Russ.)).

EDN: TJXFNR. https://doi.org/10.17816/ACEN.1359

3. Неврология. Национальное руководство. Краткое издание. Под ред. Е.И. Гусева, А.Н. Коновалова, А.Б. Гехт. М.: ГЭОТАР-Медиа. 2018; 688 с. (Neurology. National Guide. Brief Edition. Ed. by Gusev EI, Konovalov AN, Gekht AB. Moscow: GEOTAR-Media. 2018; 688 pp. (In Russ.)). ISBN: 978-5-9704-4405-4.

4. Busse A, Hensel A, Guhne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology. 2006;67(12):2176–85.

PMID: 17190940. https://doi.org/10.1212/01.wnl.0000249117.23318.e1

5. Di Carlo, Lamassa M, Baldereschi M, Inzitari M, Scafato E, Farchi G et al. CIND and MCI in the Italian elderly: Frequency, vascular risk factors, progression to dementia. Neurology. 2007;68(22):1909–16.

PMID: 17536047. https://doi.org/10.1212/01.wnl.0000263132.99055.0d

6. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008;148(6):427–34.

PMID: 18347351. PMCID: PMC2670458. https://doi.org/10.7326/0003-4819-148-6-200803180-00005

7. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C et al. Prevalence and classification of mild cognitive impairment in the cardiovascular health study cognition study: Part 1. Arch Neurol. 2003;60(10):1385–89.

PMID: 14568808. https://doi.org/10.1001/archneur.60.10.1385

8. Yang M, Sun D, Wang Y, Yan M, Zheng J, Ren J. Cognitive Impairment in heart failure: Landscape, challenges, and future directions. Front Cardiovasc Med. 2022;8:831734.

PMID: 35198608. PMCID: PMC8858826. https://doi.org/10.3389/fcvm.2021.831734

9. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol. 1999;56(3):303–8.

PMID: 10190820. https://doi.org/10.1001/archneur.56.3.303. Erratum in: Arch Neurol 1999;56(6):760.

10. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs. community-based cohorts. Arch Neurol. 2009;66(9):1151–57.

PMID: 19752306. PMCID: PMC2863139. https://doi.org/10.1001/archneurol.2009.106

11. Симерзин В.В., Фатенков О.В., Панишева Я.А., Галкина М.А., Гаглоев А.В. Возрастные инволютивные особенности когнитивных функций. Наука и инновации в медицине. 2019;4(2):21–26. (Simerzin VV, Fatenkov OV, Panisheva YaA, Galkina MA, Gagloev AV. Age-specific involutive characteristics of cognitive functions. Nauka i innovatsii v meditsine = Science & Innovations in Medicine. 2019;4(2):21–26 (In Russ.)).

EDN: XVYHVS. https://doi.org/10.35693/2500-1388-2019-4-2-21-26

12. Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D et al. Practice guideline update summary: Mild cognitive impairment (RETIRED): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126–35.

PMID: 29282327. PMCID: PMC5772157. https://doi.org/10.1212/WNL.0000000000004826

13. Bueno H, Deaton C, Farrero M, Forsyth F, Braunschweig F, Buccheri S et al.; ESC Scientific Document Group. 2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease: Developed under the auspices of the ESC Clinical Practice Guidelines Committee. Eur Heart J. 2025;46(41):4156–225.

PMID: 40878270. https://doi.org/10.1093/eurheartj/ehaf191

14. World Health Organization. Comprehensive mental health action plan 2013–2030. 2013.

URL: https://www.who.int/publications/i/item/9789240031029 (date of access – 11.09.2025).

15. Manwell LA, Barbic SP, Roberts K, Durisko Z, Lee C, Ware E et al. What is mental health? Evidence towards a new definition from a mixed methods multidisciplinary international survey. BMJ Open 2015;5(6):e007079.

PMID: 26038353. PMCID: PMC4458606. https://doi.org/10.1136/bmjopen-2014-007079

16. Chowdhury M. What is the mental health continuum model? 2019. URL: https://positivepsychology.com/mental-health-continuum-model/ (date of access – 11.09.2025).

17. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N et al.; American Heart Association Statistics Committee of the Council on Epidemiology and Prevention and the Council on Cardiovascular and Stroke Nursing. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: A scientific statement from the American Heart Association. Circulation 2014;129(12):1350–69.

PMID: 24566200. https://doi.org/10.1161/CIR.0000000000000019

18. Sokoreli I, de Vries JJ, Riistama JM, Pauws SC, Steyerberg EW, Tesanovic A et al. Depression as an independent prognostic factor for all-cause mortality after a hospital admission for worsening heart failure. Int J Cardiol 2016;220:202–7.

PMID: 27389442. https://doi.org/10.1016/j.ijcard.2016.06.068

19. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J 2015;170(6):1105–15.

PMID: 26678632. PMCID: PMC4684590. https://doi.org/10.1016/j.ahj.2015.09.013

20. Goyal P, Didomenico RJ, Pressler SJ, Ibeh C, White-Williams C, Allen LA, Gorodeski EZ; HFSA Scientific Statement Committee Members. Cognitive impairment in heart failure: A Heart Failure Society of America scientific statement. J Card Fail. 2024;30(3):488–504.

PMID: 38485295. https://doi.org/10.1016/j.cardfail.2024.01.003

21. Zuccala G, Marzetti E, Cesari M, Lo Monaco MR, Antonica L, Cocchi A et al. Correlates of cognitive impairment among patients with heart failure: Results of a multicenter survey. Am J Med. 2005;118(5):496–502.

PMID: 15866252. https://doi.org/10.1016/j.amjmed.2005.01.030

22. Dong Y, Teo SY, Kang K, Tan M, Ling LH, Yeo PSD et al. Cognitive impairment in Asian patients with heart failure: prevalence, biomarkersclinical correlates, and outcomes. Eur J Heart Fail. 2019;21(5):688–90.

PMID: 30938010. https://doi.org/10.1002/ejhf.1442

23. Huynh QL, Negishi K, De Pasquale CG, Hare JL, Leung D, Stanton T et al. Cognitive domains and postdischarge outcomes in hospitalized patients with heart failure. Circ Heart Fail. 2019;12(6):e006086.

PMID: 31146542. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006086

24. Vellone E, Chiala O, Boyne J, Klompstra L, Evangelista LS, Back M et al. Cognitive impairment in patients with heart failure: An international study. ESC Heart Fail. 2020;7(1):46–53.

PMID: 31854133. PMCID: PMC7083494. https://doi.org/10.1002/ehf2.12542

25. Agarwal KS, Kazim R, Xu J, Borson S, Taffet GE. Unrecognized cognitive impairment and its effect on heart failure readmissions of elderly adults. J Am Geriatr Soc. 2016;64(11):2296–301.

PMID: 27676328. https://doi.org/10.1111/jgs.14471

26. Grubb NR, Simpson C, Fox KA. Memory function in patients with stable, moderate to severe cardiac failure. Am Heart J. 2000;140(1):E15.

PMID: 10874251. https://doi.org/10.1067/mhj.2000.106647

27. Gure TR, Blaum CS, Giordani B, Koelling TM, Galecki A, Pressler SJ et al. Prevalence of cognitive impairment in older adults with heart failure. J Am Geriatr Soc. 2012;60(9):1724–29.

PMID: 22882000. PMCID: PMC3445700. https://doi.org/10.1111/j.1532-5415.2012.04097.x

28. Gallagher R, Sullivan A, Burke R, Hales S, Gillies G, Cameron J et al. Mild cognitive impairment, screening, and patient perceptions in heart failure patients. J Card Fail. 2013;19(9):641–46.

PMID: 24054341. https://doi.org/10.1016/j.cardfail.2013.08.001

29. Hammond CA, Blades NJ, Chaudhry SI, Dodson JA, Longstreth WT Jr, Heckbert SR et al. Long-term cognitive decline after newly diagnosed heart failure: Longitudinal analysis in the CHS (Cardiovascular Health Study). Circ Heart Fail. 2018;11(3):e004476.

PMID: 29523517. PMCID: PMC6072263. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004476

30. Jutkowitz E, MacLehose RF, Gaugler JE, Dowd B, Kuntz KM, Kane RL. Risk factors associated with cognitive, functional, and behavioral trajectories of newly diagnosed dementia patients. J Gerontol A Biol Sci Med Sci. 2017;72(2):251–58.

PMID: 27129917. PMCID: PMC5344797. https://doi.org/10.1093/gerona/glw079

31. Holm H, Bachus E, Jujic A, Nilsson ED, Wadstrom B, Molvin J et al. Cognitive test results are associated with mortality and rehospitalization in heart failure: Swedish prospective cohort study. ESC Heart Failure. 2020;7(5):2948–55.

PMID: 32810367. PMCID: PMC7524063. https://doi.org/10.1002/ehf2.12909

32. Pastva AM, Hugenschmidt CE, Kitzman DW, Nelson MB, Brenes GA, Reeves GR et al. Cognition, physical function, and quality of life in older patients with acute decompensated heart failure. J Card Fail. 2021;27(3):286–94.

PMID: 32956816. PMCID: PMC7914148. https://doi.org/10.1016/j.cardfail.2020.09.007

33. Miao F, Wang B, Zhang L, Yan X, Tang H, Cui Z et al. Distinct associations between postdischarge cognitive change patterns and 1-year outcomes in patients hospitalized for heart failure. J Card Fail. 2023;29(6):870–79.

PMID: 36764442. https://doi.org/10.1016/j.cardfail.2023.01.006

34. Sacre JW, Ball J, Wong C, Chan YK, Stewart S, Kingwell BA, Carrington MJ. Mild cognitive impairment is associated with subclinical diastolic dysfunction in patients with chronic heart disease. Eur Heart J Cardiovasc Imaging. 2018;19(3):285–92.

PMID: 28954294. https://doi.org/10.1093/ehjci/jex169

35. Kure CE, Rosenfeldt FL, Scholey AB, Pipingas A, Kaye DM, Bergin PJ et al. Relationships among cognitive function and cerebral blood flow, oxidative stress, and inflammation in older Heart failure patients. J Card Fail. 2016;22(7):548–59.

PMID: 27002943. https://doi.org/10.1016/j.cardfail.2016.03.006

36. Lee TC, Qian M, Liu Y, Graham S, Mann DL, Nakanishi K et al. Cognitive decline over time in patients with systolic heart failure: Insights from WARCEF. JACC Heart Fail. 2019;7(12):1042–53.

PMID: 31779926. PMCID: PMC6944056. https://doi.org/10.1016/j.jchf.2019.09.003

37. Ren Z. Effects of chronic heart failure on longitudinal changes of cognitive function in elderly patients. Contrast Media Mol Imaging. 2022;23:9871800.

PMID: 36226270. PMCID: PMC9525790. https://doi.org/10.1155/2022/9871800

38. Ampadu J, Morley JE. Heart failure and cognitive dysfunction. Int J Cardiol. 2015;178:12–23.

PMID: 25464210. https://doi.org/10.1016/j.ijcard.2014.10.087

39. Athilingam P, Moynihan J, Chen L, D’Aoust R, Groer M, Kip K. Elevated levels of interleukin 6 and C-reactive protein associated with cognitive impairment in heart failure. Congest Heart Fail. 2013;19(2): 92–98.

PMID: 23057677. PMCID: PMC3801169. https://doi.org/10.1111/chf.12007

40. Liori S, Arfaras‑Melainis A, Bistola V, Polyzogopoulou E, Parissis J. Cognitive impairment in heart failure: clinical implications, tools of assessment, and therapeutic considerations. Heart Failure Reviews. 2022;27(4):993–99.

PMID: 33939080. https://doi.org/10.1007/s10741-021-10118-5

41. Celutkiene J, Vaitkevic A, Jakstiene S, Jatuzis D. Cognitive decline in heart failure: more attention is needed. Cardiac Failure Review 2016;2(2):106–9.

PMID: 28785462. PMCID: PMC5490972. https://doi.org/10.15420/cfr.2016:19:2

42. Ni RSS, Mohamed Raffi HQ, Dong Y. The pathophysiology of cognitive impairment in individuals with heart failure: A systematic review. Front Cardiovasc Med. 2023;10:1181979.

PMID: 37288268. PMCID: PMC10242665. https://doi.org/10.3389/fcvm.2023.1181979

43. Ovsenik A, Podbregar M, Fabjan A. Сerebral blood flow impairment and cognitive decline in heart failure. Brain Behav. 2021;11(6):e02176.

PMID: 33991075. PMCID: PMC8213942. https://doi.org/10.1002/brb3.2176

44. Caldas JR, Panerai RB, Haunton VJ, Almeida JP, Ferreira GS, Camara L et al. Cerebral blood flow in ischemic heart failure. Am J Physiol Regul Integr Comp Physiol. 2017;312(1):R108–13.

PMID: 27927624. https://doi.org/10.1152/ajpregu.00361.2016

45. Kim JH, Shah P, Tantry US, Gurbel PA. Coagulation abnormalities in heart failure: Pathophysiology and therapeutic implications. Curr Heart Fail Rep. 2016;13(6):319–28.

PMID: 27815681. https://doi.org/10.1007/s11897-016-0308-6

46. Toledo C, Andrade DC, Diaz HS, Inestrosa NC, Del Rio R. Neurocognitive disorders in heart failure: novel pathophysiological mechanisms underpinning memory loss and learning impairment. Mol Neurobiol. 2019;56(12):8035–51.

PMID: 31165973. https://doi.org/10.1007/s12035-019-01655-0

47. Gottesman RF, Grega MA, Bailey MM, Zeger SL, Baumgartner WA, McKhann GM, Selnes OA. Association between hypotension, low ejection fraction and cognitive performance in cardiac patients. Behav Neurol. 2010;22(1–2):63–71.

PMID: 20543460. PMCID: PMC3065346. https://doi.org/10.3233/BEN-2009-0261

48. van Dalen JW, Brayne C, Crane PK, Fratiglioni L, Larson EB, Lobo A et al. Association of systolic blood pressure with dementia risk and the role of age, U-shaped associations, and mortality. JAMA Intern Med. 2022;182(2):142–52.

PMID: 34901993. PMCID: PMC8669604. https://doi.org/10.1001/jamainternmed.2021.7009

49. Carvalho C, Moreira PI. Oxidative stress: A major player in cerebrovascular alterations associated to neurodegenerative events. Front Physiol. 2018;9:806.

PMID: 30018565. PMCID: PMC6037979. https://doi.org/10.3389/fphys.2018.00806

50. Zuccala G, Cattel C, Manes-Gravina E, Di Niro MG, Cocchi A, Bernabei R. Left ventricular dysfunction: A clue to cognitive impairment in older patients with heart failure. J Neurol Neurosurg Psychiatry. 1997;63(4):509–12.

PMID: 9343133. PMCID: PMC2169754. https://doi.org/10.1136/jnnp.63.4.509

51. Gonzalez P, Machado I, Vilcaes A, Caruso C, Roth GA, Schioth H et al. Molecular mechanisms involved in interleukin 1-beta (IL-1β)-induced memory impairment. Modulation by alpha-melanocyte-stimulating hormone (α-MSH). Brain Behav Immun. 2013;34:141–50.

PMID: 23968970. https://doi.org/10.1016/j.bbi.2013.08.007

52. Peikert A, Goyal P, Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status. JACC Heart Fail. 2023;11(10):1380–93.

PMID: 37294244. https://doi.org/10.1016/j.jchf.2023.05.014

53. Rawle MJ, Cooper R, Kuh D, Richards M. Associations between polypharmacy and cognitive and physical capability: A British birth cohort study. J Am Geriatr Soc. 2018;66(5):916–23.

PMID: 29574684. PMCID: PMC6001617. https://doi.org/10.1111/jgs.15317

54. Owolabi MO, Thrift AG, Mahal A, Ishida M, Martins S, Johnson WD et al.; Stroke Experts Collaboration Group. Primary stroke prevention worldwide: Translating evidence into action. Lancet Public Health. 2022;7(1):e74–e85.

PMID: 34756176. PMCID: PMC8727355. https://doi.org/10.1016/S2468-2667(21)00230-9. Erratum in: Lancet Public Health. 2022;7(1):e14. PMID: 34756176. PMCID: PMC8727355. https://doi.org/10.1016/S2468-2667(21)00281-4

55. Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M et al. Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care. 2022;45(5):1247–51.

PMID: 35287171. PMCID: PMC9174954. https://doi.org/10.2337/dc21-2434

56. Федин А.И., Захаров В.В., Танашян М.М., Чуканова Е.И., Маджидова Е.Н., Щепанкевич Л.А., Остроумова О.Д. Результаты международного многоцентрового рандомизированного двойного слепого плацебо-контролируемого исследования оценки эффективности и безопасности последовательной терапии пациентов с хронической ишемией мозга препаратами Мексидол и Мексидол ФОРТЕ 250 (исследование МЕМО). Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(11):7–16. (Fedin AI, Zakharov VV, Tanashyan MM, Chukanova EI, Madzhidova EN, Shchepankevich LA, Ostroumova OD. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7–16 (In Russ.)).

EDN: OBNTNH. https://doi.org/10.17116/jnevro20211211117

57. Захаров В.В., Остроумова О.Д., Кочетков А.И., Клепикова М.В., Федин А.И. Международное многоцентровое рандомизированное двойное слепое плацебо-контролируемое исследование оценки эффективности и безопасности последовательной терапии пациентов с хронической ишемией мозга препаратами Мексидол® и Мексидол® ФОРТЕ 250 (исследование МЕМО): результаты субанализа у пациентов с артериальной гипертонией. Терапия. 2023;9(1):145–159. (Zakharov VV, Ostroumova OD, Kochetkov AI, Klepikova MV, Fedin AI. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol® and Mexidol® FORTE 250 in patients with chronic brain ischemia (MEMO): Subanalysis in patients with arterial hypertension.

EDN: SPQRTS. https://doi.org/10.18565/therapy.2023.1.145–159

58. Захаров В.В., Вахнина Н.В. Применение Мексидола у пациентов с легкими (умеренными) когнитивными нарушениями: результаты метаанализа. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(1):82–88. (Zakharov VV, Vakhnina NV. The use of Mexidol in patients with mild (moderate) cognitive impairment: Results of a meta-analysis. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1):82–88 (In Russ.)).

EDN: EFVDFY. https://doi.org/10.17116/jnevro202412401182

59. Щулькин А.В., Казахмедов Э.Р., Галочкин С.А., Толкачева В.В., Кобалава Ж.Д. Эффекты Мексидола у пациентов с ХИМ и ХСН II–III функционального класса. Кардиология и сердечно-сосудистая хирургия. 2020;13(5):427–434. (Shchulkin AV, Kazakhmedov ER, Galochkin SA, Tolkacheva VV, Kobalava ZhD. Effects of Mexidol in patients with chronic brain ischemia and chronic heart failure (II–III functional class). Kardiologiya i serdechno-sosudistaya khirurgiya = Russian Journal of Cardiology and Cardiovascular Surgery. 2020;13(5):427–434 (In Russ.)).

EDN: USRBIQ. https://doi.org/10.17116/kardio202013051427

60. Толкачева В.В., Карапетян Л.В., Хуцишвили Н.И., Галочкин С.А., Казахмедов Э.Р., Кобалава Ж.Д. Влияние Мексидола на улучшение когнитивного статуса и параметров качества жизни в составе комплексной терапии пациентов с хронической сердечной недостаточностью II–III функционального класса. Кардиология и сердечно-сосудистая хирургия. 2023;16(4):362–373. (Tolkacheva VV, Karapetyan LV, Khutsishvili NI, Galochkin SA, Kazakhmedov ER, Kobalava ZhD. The effect of Mexidol on the improvement of cognitive status and quality of life parameters in the complex therapy of patients with chronic heart failure II–III functional class. Kardiologiya i serdechno-sosudistaya khirurgiya = Russian Journal of Cardiology and Cardiovascular Surgery. 2023;16(4):362–373 (In Russ.)).

EDN: TNBOGS. https://doi.org/10.17116/kardio202316041362